Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Direct-acting antiviral regimens for hepatitis C genotypes
IRCT20081110001444N7Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sofosbuvir, daclatasvir and ledipasvir in hepatitis C virus infection (2 arms), sponsored by Shahid Sadoughi University of Medical Sciences. Primary endpoint: Sustained virological response at 12 weeks. Started Dec 2021; status: completed.
02
Drugs
sofosbuvirdaclatasvirledipasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on IRCT20081110001444N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20081110001444N7.